Status:
COMPLETED
The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy of AZD5423 in patients with mild asthma challenged with an inhaled allergen.
Eligibility Criteria
Inclusion
- 18-60 years of age
- Pre-bronchodilatory FEV1 ≥70% of predicted normal allergic asthmatic with a history of episodic wheeze
- Positive allergen induced early and late airway bronchoconstriction showing ≥ 20% fall in FEV1 for the early and ≥ 15% for the late response
- Positive skin prick test to common aeroallergens
Exclusion
- Any clinically significant disease or disorder
- Any clinically relevant abnormal finding at screening examinations
- Smoker or ex-smoker who has stopped smoking \< 12 months prior to study start
- Worsening of asthma or respiratory infection within 6 weeks from visit 1
- Allergen-specific immunotherapy within 6 months prior to visit 1
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT01225549
Start Date
November 1 2010
End Date
December 1 2011
Last Update
April 2 2015
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Calgary, Alberta, Canada
2
Research Site
Hamilton, Ontario, Canada
3
Research Site
Québec, Quebec, Canada
4
Research Site
Saskatoon, Saskatchewan, Canada